$NBP News

NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer

NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development

NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia

NovaBridge’s Visara Plans To Develop HT006.2.2 As VIS-102, Second Clinical-Stage Program, Expanding Its Ophthalmology Portfolio Beyond Retinal Vascular Disease Into Ocular Surface Disease

Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop

NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026

NovaBridge Biosciences H1 2026 Earnings Call: Complete Transcript

NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

NovaBridge Biosciences to Participate in September Investor Conferences

NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ...

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

NovaBridge Biosciences (NBP) Q2 2026 Earnings Call Transcript

NovaBridge Biosciences Q2 2026 Earnings Call Summary

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

NovaBridge Biosciences H1 EPS $(0.33) Misses $(0.14) Estimate

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026

NovaBridge: Rebranded, Repackaged, But Far From De-Risked

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NovaBridge Names Srishti Gupta CEO As Sean Fu Steps Down